Key points from this week’s report:
Please refer to the attached PDF for the full report.
- European stocks dropped 69 bps in the past week, marking a fourth consecutive week of decline. Friday’s move concluded a week of choppy trading as investors digested strong earnings from the telecom and energy sector against macroeconomic data such as 0.4% q/q growth in Eurozone GDP and political developments in the U.S. While Germany is expected to be the worst hit country in the Eurozone through proposed tariffs largely affecting the auto sector, pharmaceutical companies such as Zealand Pharma (ZEA.DK, -14.9%), UCB (UCB.BE; -9.3%), Bachem Holding (BANB.CH;-9.2%), and Swedish Orphan (SOBI.SE; -8.4%) also saw a sharp decline during the week due to the proposed appointment of Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services.
- The index has been making lower lows and lower highs since falling 1.25% on October 30 with stiff resistance from the declining 10-DMA, 74 bps above. At open on Monday, November 18, the index has already taken out Friday’s lows and volumes on negative days have been high. We recommend investors become highly selective with the markets and sectors to take positions. Ideally, they should wait on the sidelines as markets remain weak on inflation and geopolitical concerns but if positions need to be taken, then we would recommend only leading names from improving sectors and constructive geographies that are breaking out of proper bases behind earnings or strong fundamental factors.
- We are seeing leadership continue to narrow with the number of stocks breaking out falling to 355 while the stocks trading near the pivot of their bases has now slumped to 2,037, steadily trending lower from the 5,144 level in late August. The number of failed bases is concerning, with the number surging to 1,219, the highest level since early August when the index had dropped down as much as 479.8 (4.63% below).
